Karyopharm Therapeutics Inc
KPTI5.410USD
-0.320-5.58%
收盘 09/19, 16:00（美东）报价延迟15分钟
46.78M总市值
亏损市盈率 TTM
关于 Karyopharm Therapeutics Inc 公司
Karyopharm Therapeutics Inc. 是一家商业阶段制药公司。该公司致力于发现、开发和商业化针对核输出的药物，用于治疗癌症和其他疾病。该公司正在开发和商业化小分子选择性核输出抑制剂 (SINE) 化合物，该化合物可抑制核输出蛋白输出蛋白 1 (XPO1)。其主要资产 XPOVIO (selinexor) 与硼替佐米和地塞米松联合用于治疗已接受过至少一种先前治疗的多发性骨髓瘤成人患者。该公司正在评估 selinexor 在某些血液和实体肿瘤恶性肿瘤中的应用，包括多发性骨髓瘤、子宫内膜癌、蕈样肉芽肿 (MF) 和弥漫性大 B 细胞淋巴瘤 (DLBCL)。该公司的候选产品 eltanexor 是一种口服 SINE 化合物，与 selinexor 一样，可选择性阻断核输出蛋白 XPO1。
公司简介
公司代码KPTI
公司名称Karyopharm Therapeutics Inc
上市日期Nov 06, 2013
CEOMr. Richard A. Paulson
员工数量279
证券类型Ordinary Share
年结日Nov 06
公司地址85 Wells Avenue
城市NEWTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02459
电话16176580600
网址https://karyopharm.com/
公司代码KPTI
上市日期Nov 06, 2013
CEOMr. Richard A. Paulson
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
其他
72.51%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
其他
72.51%
股东类型
持股股东
占比
Investment Advisor
20.86%
Hedge Fund
16.35%
Research Firm
7.96%
Corporation
5.28%
Investment Advisor/Hedge Fund
4.11%
Venture Capital
1.83%
Individual Investor
1.14%
Bank and Trust
0.03%
其他
42.45%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
2023Q1
395
6.56M
86.55%
-1.62M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
139.65K
1.62%
+139.65K
--
Mar 31, 2025
The Vanguard Group, Inc.
510.29K
5.91%
-5.00
-0.00%
Mar 31, 2025
J. Wood Capital Advisors LLC
458.13K
5.3%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.88%
-1.00
-0.00%
Mar 31, 2025
Eversept Partners, LP
257.15K
2.98%
+117.90K
+84.67%
Mar 31, 2025
J.P. Morgan Securities LLC
147.42K
1.71%
+129.01K
+700.61%
Mar 31, 2025
Citadel Advisors LLC
206.91K
2.39%
-2.00
-0.00%
Mar 31, 2025
Palo Alto Investors LP
324.03K
3.75%
-3.10K
-0.95%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
188.02K
2.18%
-1.00K
-0.53%
Mar 31, 2025
BofA Global Research (US)
132.91K
1.54%
+122.13K
+1132.80%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
公告日期
类型
比率
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
